Romesh Subramanian

President and Chief Executive Officer, Marrow Therapeutics

Focused on developing transformative medicines for severe blood disorders. Romesh Subramanian, PhD, has over two decades of R&D experience in pharma and biotech as a scientist, founder and entrepreneur, and currently serves as a Venture Partner at Scion Life Sciences.

Prior to Marrow, Dr. Subramanian served as President and CEO of Ascidian Therapeutics developing RNA exon editing medicines. Previously, he was an entrepreneur in residence at Atlas Ventures and the founding CEO of Dyne Therapeutics (NASDAQ: DYN), which develops antibody conjugates for neuromuscular diseases. While at Atlas Ventures, Romesh also co-founded and led R&D at RaNA Therapeutics, later known as Translate Bio (NASDAQ:TBIO) and acquired by Sanofi (NASDAQ:SNY). Romesh also led mRNA and antibody therapeutics at Alexion and developed nucleic acid therapies for metabolic disease and oncology at Pfizer.

Dr. Subramanian obtained his BS from Loyola College, an MS from Duke University, and a PhD from Emory University.